# CJC-1295 bound to albumin > CJC-1295 with DAC | Peptide Empire — Peptide Empire examines CJC-1295’s albumin attachment, DAC and no-DAC, hormone findings and the gap in long-term benefit and safety studies. **A prolonged signal** The chemistry made a growth-hormone signal last longer. The claims about sleep, muscle and recovery spread much further. ## The attachment that prolongs action The albumin attachment is a neat piece of engineering. I appreciate CJC-1295’s solution to the duration problem. CJC-1295 was developed from the active portion of growth-hormone-releasing hormone, with changes intended to protect it from rapid breakdown. The DAC form adds a way to attach to circulating albumin. A large, familiar blood protein becomes the means of prolonging a small peptide’s presence. CJC-1295 stimulates the pituitary, the gland beneath the brain, to release growth hormone. IGF-1, another growth-related hormone, rises downstream. The [review of growth-hormone-releasing hormone and its analogues](https://pubmed.ncbi.nlm.nih.gov/39537825/) places this design within the larger effort to make hormone signals last longer. The term no-DAC usually refers to Modified GRF (1-29), which retains protective substitutions but lacks that albumin attachment. It acts for less time. Treating the two names as interchangeable erases the very design feature that made the longer-acting research interesting. ![A small peptide chain attached to a larger folded protein sculpture](images/albumin-tether.webp) *A sculptural interpretation of a peptide attached to albumin. The relative forms illustrate the attachment idea; they are not a measured molecular structure.* ## Hormone studies in volunteers In the [early healthy-adult study](https://pubmed.ncbi.nlm.nih.gov/16352683/), mean growth hormone increased twofold to tenfold for at least six days. IGF-1 remained elevated for nine to eleven days; after repeated research administration, the elevation persisted for as long as twenty-eight days. A separate [small study in healthy men found that growth-hormone pulses persisted](https://pubmed.ncbi.nlm.nih.gov/17018654/). A higher overall hormone level could coexist with the ordinary rise and fall of secretion. The finding explains something about pituitary behaviour under sustained stimulation. These results establish a pharmacological effect. Claims of stronger muscles, better sleep or faster recovery demand another journey from those blood measurements. I cannot follow that journey on the evidence described here. The studies described here did not establish those benefits. ## Blood proteins and identification The quieter follow-up is worth a place beside the hormone figures. A [study of 11 healthy young men found changes in several blood proteins](https://pubmed.ncbi.nlm.nih.gov/19386527/), with some signals correlating with IGF-1. That is a search for biological markers of the drug’s action; it supplies another way to observe the response. Then the literature takes a different turn. Investigators [identified CJC-1295 in an unknown pharmaceutical preparation using analytical chemistry](https://doi.org/10.1002/dta.233), in an anti-doping context. The intended ingredient and the contents of a preparation become separate questions. This is an especially revealing turn in the record: the same compound appears in work on prolonging a hormone signal and in work on identifying an unknown mixture. ## Sleep and training reports People describe deeper sleep, less post-training soreness, gradual fat loss or more energy. They also describe puffiness, tingling hands, headache, fatigue and higher blood sugar. These are anecdotal accounts, not clinical evidence for either a benefit or an incidence of harm. Some accounts involve several substances, changes in training or altered eating. An improvement in that setting has several possible explanations. I want CJC-1295 tested against sleep and recovery themselves, with the accompanying changes separated out. A growing list of reported effects makes that experiment more necessary. ## Approval and lasting safety CJC-1295 is not approved for human use. The available healthy-adult work is small and largely concerned with hormone behaviour. The [sustained hormone elevations](https://pubmed.ncbi.nlm.nih.gov/16352683/) and [wider GHRH-analogue pharmacology](https://pubmed.ncbi.nlm.nih.gov/39537825/) give reasons to consider fluid retention, blood-sugar effects and unwanted tissue growth. Their frequency and long-term consequences with CJC-1295 have not been established in large trials. Product identity adds a separate uncertainty, illustrated by the [analysis of the unknown preparation](https://doi.org/10.1002/dta.233). Research amounts describe an experiment and supply no personal treatment instructions. CJC-1295’s engineering impresses me; the daily-life claims still need their own clinical work. --- Peptide Empire audits how peptide claims cross from mechanism into medicine; it is an independent literature digest, not clinical direction.